Researchers have reported a result that deserves attention in preclinical aging science: a one-time gene therapy increased median lifespan in aged male mice while also improving several measures of health during later life.
The treatment used an adeno-associated virus, or AAV, to deliver the gene for fibroblast growth factor 21, better known as FGF21, into skeletal muscle. The injected muscles then produced and released FGF21 into the bloodstream, allowing the signal to reach organs throughout the body.
In the main survival experiment, male mice received the treatment at 13 months of age. Median lifespan rose from 28.14 months in the control group to 33.92 months in the treated group, an increase of 20.54%. The experiment included 61 control mice and 32 mice treated with AAV-FGF21.
That is an important mouse result. It is also a result with firm boundaries. The lifespan finding came from male mice, not humans, and it does not establish that the same intervention would be safe or effective in people.
What researchers tested
FGF21 is a hormone involved in energy use, glucose and fat metabolism, and the body’s response to nutritional and cellular stress. Although its name includes the phrase fibroblast growth factor, FGF21 functions primarily as an endocrine signal. That means it can be released by one tissue and influence other parts of the body through the circulation.
The research team, led by investigators at the Universitat Autònoma de Barcelona in Spain, used an AAV serotype 1 vector carrying a mouse FGF21 gene. AAV vectors are modified viral shells that can deliver genetic instructions into cells. In this case, the vector was injected into skeletal muscles in the hind limbs. The goal was to turn a limited amount of muscle tissue into a durable source of circulating FGF21.
The main cohort received 3 × 10¹¹ viral genomes per mouse. Age-matched mice received a non-coding AAV vector as the control. The researchers also studied younger untreated mice for comparison and examined treatment in additional aged and geriatric male and female cohorts.
The study followed animals across later life, with the broader program running for 27 months. Measurements showed sustained FGF21 production from the injected muscle. This matters because the intervention was designed as a lasting biological source of the hormone, not a short course of a conventional drug.
What happened in the mice
The clearest survival result came from males treated at 13 months. Their median lifespan increased by 5.78 months, from 28.14 to 33.92 months. Expressed as a percentage, that was a 20.54% increase in median lifespan.
The paper also reported a broad pattern of health-related changes. Treated mice maintained lower body weight and adiposity without a reported reduction in food intake. They showed better insulin sensitivity and glucose control, along with increased energy expenditure.
The benefits were not limited to metabolic measurements. The researchers reported preserved liver detoxification capacity, less age-related kidney disease, improved cardiac health, and better muscular function. Behavioral testing also indicated improved cognition in treated animals.
Tissue analyses helped explain why a signal produced in muscle could affect the whole body. Across different organs, the response was associated with improved mitochondrial function, better proteostasis, and reductions in inflammation, fibrosis and amyloid accumulation. Proteostasis is the set of cellular systems that build, fold, maintain and remove proteins. Its decline is one feature of aging because damaged or misfolded proteins can accumulate and disrupt cell function.
The study also found activation of AMPK signaling. AMPK acts as a cellular energy sensor. When energy is limited, it helps cells shift toward conserving resources, using stored fuel and maintaining essential processes. The findings suggest that FGF21 did not produce one identical response everywhere. Instead, different tissues adapted to the circulating signal in ways relevant to their own metabolism and maintenance.
Several functional and tissue outcomes were studied in both male and female mice, but the headline lifespan figure should not be presented as a confirmed result in both sexes. The reported survival experiment underlying the 20.54% increase used males. Further work is needed to establish whether females receive a comparable lifespan benefit.
Why FGF21 is interesting in aging research
Aging affects many systems at once. Metabolism becomes less flexible, inflammation tends to rise, damaged proteins become harder to clear, mitochondrial performance can decline, and fibrosis can accumulate in organs. A treatment that influences several of these processes could be more relevant to healthspan than one that changes a single biomarker.
FGF21 is especially interesting because it connects energy balance with cellular stress responses. In this study, the hormone was linked to tissue-specific changes rather than a simple whole-body metabolic switch. The liver, kidney, heart, muscle, fat and brain did not all respond in the same way, but the overall pattern favored better organ function and cellular maintenance.
This is similar in principle to research showing that active muscle can influence distant organs through circulating signals. The Lifespan Brief recently examined that idea in a study of self-contracting engineered muscle grafts. The two approaches are different, but both treat skeletal muscle as more than a structure for movement. Muscle can also serve as a signaling organ and, with gene therapy, as a biological production site.
Why late-life treatment matters
Many lifespan experiments begin before animals have developed meaningful age-related decline. That can be useful for understanding biology, but it does not closely resemble the challenge of treating an older person who already has accumulated risk and tissue damage.
Here, the main treatment began when the mice were 13 months old, and additional experiments included older and geriatric animals. The researchers therefore tested whether the intervention could still produce benefits after early adulthood rather than requiring lifelong genetic modification.
That improves the study’s relevance within preclinical geroscience. It does not eliminate the species gap. A 13-month-old mouse is not a precise biological equivalent of a particular human age, and aging pathways can respond differently across species.
What the study does not show
This study does not show that FGF21 gene therapy slows aging in people. It does not establish an appropriate human dose, prove long-term human safety or show that persistent FGF21 expression would have the same effects in a human body.
AAV delivery also raises practical and medical questions. People can have pre-existing immunity to particular AAV types. Immune reactions can limit treatment or make repeat dosing difficult. Manufacturing a vector at human scale is more demanding than dosing a mouse, and long-lasting gene expression can be difficult to adjust if unwanted effects emerge.
FGF21 biology adds another layer of uncertainty. Human trials of engineered FGF21-like drugs have explored metabolic disease, but a drug that is given at controlled intervals is not the same as gene therapy that continuously produces the hormone. Long-term exposure could affect tissues or pathways that were not fully captured in the mouse study.
The study also has commercial context worth noting. Several authors are co-inventors on patent applications involving AAV vectors for metabolic diseases. Senior author Fátima Bosch is a member of the scientific advisory board of Kriya Therapeutics, which is developing FGF21 gene therapy. These disclosures do not invalidate the findings, but they strengthen the case for independent replication.
What comes next
The most useful next step is not speculation about human life extension. It is careful replication and translation.
Independent laboratories would need to confirm the survival and healthspan findings. Larger studies should test both sexes with adequately powered survival cohorts and examine whether the benefits depend on starting age, dose, baseline metabolic health or mouse strain. Researchers also need to determine which outcomes arise directly from FGF21 signaling and which follow secondarily from reduced fat mass and improved glucose control.
Long-term safety studies in additional animal models will be essential. They should examine immune responses, effects on bone and other endocrine systems, the durability and controllability of expression, and any late adverse effects. It will also be important to compare gene therapy with less permanent approaches, such as long-acting FGF21 analogues, to learn whether similar benefits can be achieved with greater control.
The finding is significant because it combined a substantial median lifespan increase with functional and multi-organ improvements after treatment began in later life. For now, its proper place is as promising preclinical evidence and a strong reason to investigate FGF21 more deeply, not as evidence that an anti-aging gene therapy for people has arrived.
Primary source: Jimenez V, Sacristan V, Garcia M, et al. AAV-mediated FGF21 gene therapy promotes health span extension by whole-body tissue-specific adaptations. *Molecular Therapy*. 2026;34(8):4546-4568.
Supporting source: Universitat Autònoma de Barcelona research summary
Disclosure noted in the paper: Several authors are co-inventors on patent applications involving AAV vectors for metabolic diseases. Fátima Bosch is a member of the scientific advisory board of Kriya Therapeutics.